Short interfering RNAs (siRNA) are a powerful class of genetic medicines whose clinical
translation can be hindered by their suboptimal delivery properties in vivo. Here, we provide …

Pancreatic cancer is an aggressive cancer with a poor prognosis. Metabolic abnormalities
are one of the hallmarks of pancreatic cancer, and pancreatic cancer cells can adapt to …

The success of personalized medicine in oncology relies on using highly effective and
precise therapeutic modalities such as small interfering RNA (siRNA) and monoclonal …

Rapid advances in nucleic acid therapies highlight the immense therapeutic potential of
genetic therapeutics. Lipid nanoparticles (LNPs) are highly potent nonviral transfection …

Abstract The Kirsten Rat Sarcoma Virus (KRAS) oncoprotein, one of the most prevalent
mutations in cancer, has been deemed undruggable for decades. The hypothesis of this …

Background In the tumor microenvironment (TME), tumor-associated macrophages (TAMs)
play a key immunosuppressive role that limits the ability of the immune system to fight …

For cystic fibrosis patients, a lung-targeted gene therapy would significantly alleviate
pulmonary complications associated with morbidity and mortality. However, mucus in the …

Breast cancer (BC) prevails as a major burden on global healthcare, being the most
prevalent form of cancer among women. BC is a complex and heterogeneous disease, and …

Small interfering RNAs (siRNAs) are promising therapeutic strategies, and five siRNA drugs
have been approved by the Food and Drug Administration (FDA) and the European …

Nucleic acid therapy is currently the most promising method for treating tumors and genetic
diseases and for preventing infectious diseases. However, the biggest obstacle to this …